Morphosys AG - ADR

MorphoSys AG operates as a commercial-stage biopharmaceutical company. It uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. The firm also engages in the development and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MorphoSys AG is a biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.

The mean of analysts' price targets for MorphoSys AG Unsponsored ADR (MOR) points to a 213.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe MorphoSys AG Unsponsored ADR (MOR) Could Rally 213%: Here's is How to Trade

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Minjuvi is a new therapeutic option for eligible DLBCL patients in Switzerland addressing an urgent unmet medical need In Switzerland each year approximately 500 patients are diagnosed with relapsed or refractory DLBCL [1] PLANEGG and MUNICH, GERMANY and MORGES, SWITZERLAND / ACCESSWIRE / March 22, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) and Incyte (INCY) today announced that the Swiss agency for therapeutic products (Swissmedic), has granted temporary approval for Minjuvi(R) (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after at least one prior line of systemic therapy including an anti-CD20 antibody, who are not eligible for autologous stem cell transplant (ASCT). Incyte holds exclusive commercialization rights for Minjuvi in Switzerland.

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q4 2021 Results - Earnings Call Transcript

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and full year 2021. "In 2021, we accelerated our vision to become a leader in hematology/oncology with the acquisition of Constellation Pharmaceuticals which expanded our late-stage pipeline," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. "We are proud that approximately 2,000 patients have been treated with Monjuvi in the U.S. since launch and continue to ha

MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN) Clinical Practice Guidelines (NCCN Guidelines(R)) in Oncology for B-cell Lymphomas have been updated, and the designation for Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide is now a Preferred Regimen for second-line therapy in patients with Diffuse Large B-cell Lymphoma (DLBCL) who are not candidates for transplant. "Updates to NCCN Guidelines are made periodically when additional efficacy and safety data are available, providing current information on the use of cancer therapies," said Joe Horvat, U.S. General Manager, MorphoSys.

National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET (8:00 pm GMT; 4:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 17, 2022 at 1:00 pm CET (12:00 pm GMT; 8:00 am EDT) to present results for the financial year 2021 and provide an outlook for 2022.

Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) announces today that it will account for a non-cash impairment charge on goodwill in the amount of approximately € 231 million.

MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021

Sierra Oncology

Sierra Oncology got a boost on Monday, releasing some very strong data in relation to its lead asset Momelotinib.

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million) Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 18, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) today reported preliminary Monjuvi (R) U.S. net product sales for the full year of 2021 and provided financial guidance for 2022. Preliminary Monjuvi (tafasitamab-cxix) U.S. net product sales are US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full year of 2021.

MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40 th Annual J.P.

MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference

MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis Data presented during poster and oral sessions at the 63rd American Society of Hematology Annual Meeting and Exposition Latest results from the MANIFEST trial underscore the rationale to further explore pelabresib in combination with ruxolitinib in MANIFEST-2, a global, Phase 3, randomized, double-blind trial in treatment-naïve patients with myelofibrosis PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) presented the latest data from the ongoing MANIFEST study, an open-label, Phase 2 clinical trial of pelabresib, an investigational BET inhibitor, in patients with myelofibrosis, a rare bone marrow cancer for which only limited treatment options are available. These latest results, which included more patients and longer-term follow-up than previously reported data, suggest the potential of pelabresib in the treatment of myelofibrosis.

MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

Incyte

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies - Results from the retrospective cohort analysis indicate significant overall survival improvement compared with Pola-BR and R2 BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / December 11, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), and Incyte (NASDAQ:INCY) today announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi(R)) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). These treatments include polatuzumab vedotin plus bendamustine and rituximab (Pola-BR), rituximab plus lenalidomide (R2), and CD19 chimeric antigen receptor T-cell (CAR-T) therapies.

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

BOSTON & WILMINGTON, Del.--(BUSINESS WIRE)--MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (NASDAQ:INCY) today announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi®) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). These treatments include polatuzumab vedotin plus bendamustine and ritu

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022 Dear Madam/Sir, Please note MorphoSys' financial reporting dates 2022 as follows: Publication of Interim Statement / Report Conference Call Year-End Results 2021 March 16, 2022 // 10 pm CET(5 pm EDT; 9 pm GMT) March 17, 2022 // 2 pm CET(9 am EDT; 1 pm GMT) First Quarter Interim Statement 2022 May 4, 2022 // 10 pm CEST(4 pm EDT; 9 pm BST) May 5, 2022 // 2 pm CEST(8 am EDT; 1 pm BST) Half-Year Report 2022 August 3, 2022 // 10 pm CEST(4 pm EDT; 9 pm BST) August 4, 2022 // 2 pm CEST(8 am EDT; 1 pm BST) Third Quarter Interim Statement 2022 Nov. 16, 2022 // 10 pm CET(4 pm EST; 9 pm GMT) Nov. 17, 2022 // 2 pm CET(8 am EST; 1 pm GMT) Annual General Meeting May 18, 2022 For a direct import of the dates to your calendar, please visit our corporate website: https://www.morphosys.com/media-and-investors/morphosys-events#company-calendar About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need.

Corporate Calendar 2022

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q3 2021 Results - Earnings Call Transcript

Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-Q Ten abstracts, including two oral presentations, accepted at upcoming ASH Pelabresib data for arm 3 of MANIFEST study to be presented at ASH confirm prior data Felzartamab demonstrated proof-of-concept in patients with aMN at Kidney Week PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 11, 2021 / MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports financial results for the third quarter and the first nine months of 2021. "Monjuvi sales continued to build momentum in the third quarter where we saw a broadening of the prescriber base and increased utilization in second-line patients," said Jean-Paul Kress, M.D.

MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pursue other opportunities.

MorphoSys Announces Departure of Roland Wandeler

Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) presented interim results from the M-PLACE study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN) on November 4-7. The poster entitled "Felzartamab in patients with anti-phospholipase A2 receptor autoantibody positive (anti-PLA2R+) membranous nephropathy (MN): Interim results from the M-PLACE study" shows data from the ongoing Phase 1b/2a, proof of concept, open-label, multicenter study designed to assess the safety and efficacy of felzartamab in adults with high anti-PLA2R-positive MN, an autoimmune kidney disease and a leading cause of nephrotic syndrome in adults.

MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting

- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational data - MANIFEST update on pelabresib monotherapy in patients with myelofibrosis - Expanded Real-World RE-MIND2 dataset comparing outcomes for tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T in relapsed/refractory diffuse large B-Cell lymphoma PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data on approved and clinical-stage therapeutics will be presented during the American Society of Hematology (ASH) Annual Meeting from December 11-14 in Atlanta, Georgia United States. Ten abstracts were accepted, including two oral presentations, from the comprehensive MorphoSys portfolio, including abstracts for the BET inhibitor pelabresib, which MorphoSys added to its pipeline through the acquisition of Constellation Pharmaceuticals.

MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting

The average of price targets set by Wall Street analysts indicates a potential upside of 71.3% in MorphoSys AG Unsponsored ADR (MOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think MorphoSys AG Unsponsored ADR (MOR) Could Surge 71%: Read This Before Placing a Bet

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to € 18.6 million (US$ 22 million) for the third quarter of 2021 and € 46.4 million (US$ 55.5 million) for the first nine months of 2021. Monjuvi (R) is being co-commercialized by Incyte and MorphoSys in the United States.

MorphoSys AG Announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN). IgAN, also known as Berger's disease, is a chronic and debilitating autoimmune disease affecting the kidneys and the most common glomerular disease worldwide.

MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

MorphoSys AG Unsponsored ADR (MOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

MorphoSys AG Unsponsored ADR (MOR) Upgraded to Strong Buy: Here's What You Should Know

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, for the treatment of people living with Alzheimer's disease (AD). This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies.

MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease

iShares Cohen & Steers REIT ETF

iShares U.S. Real Estate ETF

Invesco KBW Premium Yield Equity REIT ETF

Global X SuperDividend REIT ETF

Pacer Funds Trust-Pacer Benchmark Data & Infrastructure Real Estate Sector ETF

Global X Data Center REITs & Digital Infrastructure ETF

Real Estate Select Sector SPDR Fund

The U.S. real estate sector is in the pink this year. Rising inflation, uptick in home prices, booming cloud business and attractive yield

News for Morphosys AG - ADR Stock (MOR)